

Dialysis Event Surveillance Form

*required for saving

Patient Information		
Facility ID: *Patient ID: Secondary ID #: Patient Name, Last: *Sex: F-Female M-Male	Event ID #: Social Security #: Medicare #: First: Middle: *Date of Birth:	
Race (Select all that apply): American Indian or Alaska Native Asian Black or African American Middle Eastern or North African Native Hawaiian or Pacific Islander White Unknown Declined to respond Ethnicity: Hispanic or Latino Not Hispanic or Latino Unknown Declined to respond		
Event Information		
*Event Type: DE – Dialysis Event *Date of Event: *Location: *Was the patient admitted/readmitted to the dialysis facility on this dialysis event date? ☐ Yes ☐ No *Transient Patient ☐ Yes ☐ No		
Risk Factors		
*All Vascular Access Types Present: (check all that apply) Access placement date (mm/yyyy):		
☐ Fistula Buttonhole? ☐ Yes ☐ No ☐ Graft ☐ Tunneled central line ☐ Non-tunneled central line ☐ Other vascular access device	____/____/____ ____/____/____ ____/____/____ ____/____/____ ____/____/____	☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown ☐ Unknown
Is this a catheter-graft hybrid? ☐ Yes ☐ No Vascular access comment: _____		
*Access used for dialysis at the time of the event: (if more than one access was used for the dialysis treatment, please indicate the access with the higher risk of infection)		
☐ Fistula ☐ Graft ☐ Tunneled central line	☐ Non-tunneled central line ☐ Other vascular access device ☐ Catheter-Graft hybrid	
Event Details		
*Specify Dialysis Event: (check at least one)		
☐ IV antimicrobial start		
*Date of IV antimicrobial start:		
*Was vancomycin the antimicrobial used for this start? ☐ Yes ☐ No *Was this a new outpatient dialysis facility start or a continuation of a course initiated outside of the dialysis facility?		

Dialysis Event Surveillance Form

☐ New antimicrobial start ☐ Continuation of antimicrobial

*If new antimicrobial start, was a blood sample collected for culture? ☐ Yes ☐ No

☐ **Positive blood culture**

(*specify organism and antimicrobial susceptibilities on pages 2-3)

*Date of Positive blood culture: _____

* What is the suspected source of the organism or organisms identified on the positive blood culture?

☐ Vascular access ☐ A source other than the vascular access ☐ Contamination ☐ Uncertain

*Where was this positive blood culture collected?

☐ Dialysis clinic ☐ Hospital (on the day of or the day following admission) or E.D. ☐ Other location

☐ **Pus, redness, or increased swelling at vascular access site**

*Check the access site(s) with pus, redness, or increased swelling:

☐ Fistula ☐ Graft ☐ Tunneled ☐ Non-tunneled central line ☐ Other vascular access device
☐ Catheter-Graft central line Hybrid

*Date of pus, redness, and increased swelling: _____

*Specify Problem(s): (check one or more)

☐ Fever $\geq 37.8^{\circ}\text{C}$ (100°F) oral ☐ Chills or rigors ☐ Drop in blood pressure
☐ Wound (NOT related to vascular access) with pus or increased redness ☐ Urinary tract infection
☐ Cellulitis (skin redness, heat, or pain without open wound) ☐ Pneumonia or respiratory infection
☐ Other problem (specify): _____ ☐ None

*Specify Outcomes:

Loss of vascular	☐ Yes	☐ No	☐ Unknown
Hospitalization	☐ Yes	☐ No	☐ Unknown
Death	☐ Yes	☐ No	☐ Unknown

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 50 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.502 (Front) Rev 10, v8.6

Dialysis Event Surveillance Form

Pathogen #	Gram-positive Organisms									
_____	<i>Staphylococcus coagulase-negative</i> (specify species if available): _____		VANC SIR N	CEFOX/OX SR N						
_____	____ <i>Enterococcus faecium</i> ____ <i>Enterococcus faecalis</i> ____ <i>Enterococcus</i> spp. (Only those not identified to the species level)		DAPTO SS-DD NS N	GENTHL ⁵ SR N	LNZ SIR N	VANC SIR N				
_____	<i>Staphylococcus aureus</i>		CIPRO/LEVO/MOXI SIR N	CLIND SIR N	DAPTO SNS N	DOXY/MINO SIR N	ERYTH SIR N	GENT SIR N	LNZ SR N	
			OX/CEFOX/METH SIR N	RIF SIR N	TETRA SIR N	TIG SNS N	TMZ SIR N	VANC SIR N	CEFTAR SS-DD I R	
Pathogen #	Gram-negative Organisms									
_____	<i>Acinetobacter</i> (specify species) _____		AMK SIR N	AMPSUL SIR N	AZT SIR N	CEFEP SIR N	CEFTAZ/CEFOT/CEFTRX SIR N		CIPRO/LEVO SIR N	COL/PB SIR N
			GENT SIR N	IMI SIR N	MERO/DORI SIR N	PIP/PIPTAZ SIR N	TETRA/DOXY/MINO SIR N			
			TMZ SIR N	TOBRA SIR N						
_____	<i>Escherichia coli</i>		AMK SIR N	AMP SIR N	AMPSUL/AMXCLV SIR N	AZT SIR N	CEFAZ SIR N	CEFEP SI/S-DDRN	CEFOT/CEFTRX SIR N	
			CEFTAZ SIR N	CEFUR SIR N	CEFOX/CTET SIR N	CEFTAVI SR N	CEFTOTAZ SIR N	CIPRO/LEVO/MOXI SIR N	COL/PB [†] SIR N	
			ERTA SIR N	GENT SIR N	IMI SIR N	MERO/DORI SIR N	PIPTAZ SIR N	TETRA/DOXY/MINO SIR N		
			TIG SIR N	TMZ SIR N	TOBRA SIR N	IMIREL SIR N	MERVAB SIR N			
_____	<i>Enterobacter</i> (specify species) _____		AMK SIR N	AMP SIR N	AMPSUL/AMXCLV SIR N	AZT SIR N	CEFAZ SIR N	CEFEP SI/S-DDRN	CEFOT/CEFTRX SIR N	
			CEFTAZ SIR N	CEFUR SIR N	CEFOX/CTET SIR N	CIPRO/LEVO/MOXI SIR N	COL/PB SIR N	CEFTAVI SR N		
			ERTA SIR N	GENT SIR N	IMI SIR N	MERO/DORI SIR N	PIPTAZ SIR N	TETRA/DOXY/MINO SIR N		
			TIG SIR N	TMZ SIR N	TOBRA SIR N	CEFTOTAZ SIR N	IMIREL SIR N	MERVAB SIR N		
_____	<i>Klebsiella pneumonia</i>		AMK SIR N	AMP SIR N	AMPSUL/AMXCLV SIR N	AZT SIR N	CEFAZ SIR N	CEFEP SI/S-DDRN	CEFOT/CEFTRX SIR N	

Dialysis Event Surveillance Form

_____ <i>Klebsiella oxytoca</i>	CEFTAZ SIR N	CEFUR SIR N	CEFOX/CTET SIR N	CIPRO/LEVO/MOXI SIR N	COL/PB* SIR N	CEFTAVI SR N
_____ <i>Klebsiella aerogenes</i>	ERTA SIR N	GENT SIR N	IMI SIR N	MERO/DORI SIR N	PIPTAZ SIR N	TETRA/DOXY/MINO SIR N
	TIG SIR N	TMZ SIR N	TOBRA SIR N	CEFTOTAZ SIR N	IMIREL SIR N	MERVAB SIR N

Pathogen #	Gram-negative Organisms									
_____	<i>Pseudomonas aeruginosa</i>	AMK SIR N	AZT SIR N	CEFEP SIR N	CEFTAZ SIR N	CIPRO/LEVO SIR N	COL/PB SIR N	GENT SIR N		
		IMI SIR N	MERO/DORI SIR N		PIP/PIPT SIR N	CEFTAVI SR N	TOBRA SIR N	CEFTOTAZ SIR N		
Pathogen #	Fungal Organisms									
_____	<i>Candida</i> (specify species if available)	ANID SIR N	CASPO SNS N	FLUCO SS-DD R N	FLUCY SIR N	ITRA SS-DD R N	MICA SNS N	VORI SS-DD R N		
Pathogen #	Other Organisms									
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N
_____	Organism 1 (specify) _____	_____ D rug 1 SIR N	Drug 2 SIR N	Drug 3 SIR N	Drug 4 SIR N	_____ D rug 5 SIR N	Drug 6 SIR N	Drug 7 SIR N	Drug 8 SIR N	Drug 9 SIR N

Dialysis Event Surveillance Form

Result Codes

S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested

§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic

† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4

Drug Codes:

AMK = amikacin	CEFTOTAZ = ceftolozane/tazobactam	FLUCY = flucytosine	OX = oxacillin
AMP = ampicillin	CEFTOX = ceftriaxone	GENT = gentamicin	PB = polymyxin B
AMPSUL = ampicillin/sulbactam	CEFTUR = cefuroxime	GENTHL = gentamicin –high level test	PIP = piperacillin
AMXCLV = amoxicillin/clavulanic acid	CTET = cefotetan	IMI = imipenem	PIPTAZ = piperacillin/tazobactam
ANID = anidulafungin	CIPRO = ciprofloxacin	IMIREL = imipenem/relebactam	RIF = rifampin
AZT = aztreonam	CLIND = clindamycin	ITRA = itraconazole	TETRA = tetracycline
CASPO = caspofungin	COL = colistin	LEVO = levofloxacin	TIG = tigecycline
CEFAZ = cefazolin	DAPTO = daptomycin	LNZ = linezolid	TMZ = trimethoprim/sulfamethoxazole
CEFEF = cefepime	DORI = doripenem	MERO = meropenem	TOBRA = tobramycin
CEFOT = cefotaxime	DOXY = doxycycline	MERVAB = meropenem/vaborbactam	
CEFOX = ceftazidime	ERTA = ertapenem	METH = methicillin	VANC = vancomycin
CEFTAR = Ceftaroline	ERYTH = erythromycin	MICA = micafungin	VORI = voriconazole
CEFTAVI = ceftazidime/avibactam	FLUCO = fluconazole	MINO = minocycline	
CEFTAZ = ceftazidime		MOXI = moxifloxacin	

Custom Fields

Label	Label

Comments